SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants
April 21, 2022 16:01 ET
|
Scynexis
JERSEY CITY, N.J., April 21, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants...
SCYNEXIS to Present Positive Interim Data from Ongoing FURI and CARES Studies at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Being Held April 23-26 in Lisbon, Portugal
April 20, 2022 08:30 ET
|
Scynexis
JERSEY CITY, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Secures Additional Commercial Insurance Formulary Coverage for BREXAFEMME® (ibrexafungerp tablets), Providing Access to an Estimated 93 Million Commercially-Insured Lives
April 19, 2022 08:30 ET
|
Scynexis
JERSEY CITY, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS to Participate in Upcoming April Women’s Health Medical Conferences
April 04, 2022 09:59 ET
|
Scynexis
JERSEY CITY, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 29, 2022 07:00 ET
|
Scynexis
BREXAFEMME® (ibrexafungerp tablets), launched in August 2021, achieved net revenues of $1.1 million in 2021. Fourth quarter 2021 net revenues were $0.6 million.As of the end of 2021, BREXAFEMME was...
SCYNEXIS to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update
March 24, 2022 08:30 ET
|
Scynexis
JERSEY CITY, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Named to Fast Company’s 2022 Top 50 List of the World’s Most Innovative Companies
March 08, 2022 08:30 ET
|
Scynexis
JERSEY CITY, N.J., March 08, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 04, 2022 17:00 ET
|
Scynexis
JERSEY CITY, N.J., March 04, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS to Participate in Upcoming Scientific Conferences and Events
March 02, 2022 08:30 ET
|
Scynexis
JERSEY CITY, N.J., March 02, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and...
SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, Clearing the Way for Regulatory Submission and Potential Approval of Additional Indication by End of 2022
February 10, 2022 07:36 ET
|
Scynexis
Ibrexafungerp, the only fungicidal oral treatment for vaginal yeast infections, successfully achieved statistically significant superiority over placebo for the primary and key secondary study...